摘要
新生血管性年龄相关性黄斑变性又称为湿性年龄相关性黄斑变性（wAMD），是世界上老年人主要致盲疾病之一，抗血管内皮生长因子（VEGF）药物的玻璃体注射疗法是目前治疗wAMD的主要方法。然而在长期的随诊中发现，部分患者经抗VEGF治疗后视力并未得到明显改善甚至下降，或视力提高后不能长期维持，因此眼科医师应该关注相关疗效的影响因素。影响wAMD疗效的因素是多方面的，包括抗VEGF药物治疗wAMD的局限性、患者自身的条件、脉络膜新生血管（CNV）病灶的特征、治疗方案的制定和执行等。CNV病灶的影像学表现及治疗时机可作为疗效预后判断的指标，而治疗方案的合理制定和优化是提高疗效的可能措施。分析和了解影响wAMD疗效的因素可为制定患者个体化治疗方案和达到最好的视力收益提供依据，眼科医师应该充分认识wAMD个体化治疗的重要性。
Neovascular age-related macular degeneration is also known as wet age-related macular degeneration （wAMD） , which is now one of potentially blinding diseases in elder population worldwide. The application of anti-vascular endothelial growth factor （VEGF） drugs is becoming the first-line therapy for wAMD at present. However,during the long-term follow up,we find that the vision of some patients dose not improve even falls after treatment, or the vision is unable to keep for a long term after its improvement. Hence,to find the key factors that affect the therapeutical effect is the focus issue nowadays. There are many factors that affect wAMD curative effect, including the limitation of drug itself, the personal conditions of the patients, the features of the choriodal neovascularization （CNV） , the formulation and implementation of the treatment regimen, etc. Imaging features of CNV and treatment timing can serve as the available indexs to analyze the prognosis. In addition,reasonable and optimized managing regimens for wAMD probably is an approach to improve the treating effect. Understanding of the factors that affect curative effect of wAMD is benefit for us to setup the individualized therapy and achieve the best vision. Ophthalmologists should fully recognize the importance of wAMD individualized treatment and management.
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2016年第1期1-4,共4页
Chinese Journal Of Experimental Ophthalmology
基金
基金项目：国家自然科学基金项目（81441026）
北京市自然科学基金项目（7152123）
首都特色临床研究项目（Z151100004015147）
